Sanofi (SNY) has received US Food and Drug Administration accelerated approval for Tzield to delay the decline in endogenous insulin production in children aged 8 to 17 years recently diagnosed with stage 3 type 1 diabetes, the company said Friday.

The approval was supported by data from a phase 3 study in which Tzield significantly slowed the decline in mean C-peptide levels, compared with placebo, the company said.

Adverse events observed in the study were consistent with previous findings, according to the company.